Journal of pediatric hematology/oncology · 2026
Clinical Experience With RIST-Based Multimodality Therapy in Relapsed Ewing Sarcoma: A Descriptive Single-center Case Series.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Asleh Mahdi, Eshel Yotam, Ben Harosh Miriam, Khalaila Aya, Abu Quider Abed, Levin Daniel, Miskin Hagit
Аннотация
BACKGROUND: Outcomes for relapsed Ewing sarcoma remain poor. The RIST regimen (rapamycin, irinotecan, dasatinib, temozolomide) provides a targeted biological alternative to standard salvage chemotherapy.
METHODS: We report 3 patients treated with RIST for relapsed Ewing sarcoma.Results:One patient with measurable disease achieved an early partial response before progressing at 9 months. Two patients received RIST as post-local-therapy consolidation with no evidence of disease, maintaining disease control for 41 and 44 months. Toxicities were manageable and primarily hematologic, without treatment discontinuations.
CONCLUSION: Prolonged outpatient RIST administration is feasible, and its role as multimodality consolidation warrants further prospective evaluation.
METHODS: We report 3 patients treated with RIST for relapsed Ewing sarcoma.Results:One patient with measurable disease achieved an early partial response before progressing at 9 months. Two patients received RIST as post-local-therapy consolidation with no evidence of disease, maintaining disease control for 41 and 44 months. Toxicities were manageable and primarily hematologic, without treatment discontinuations.
CONCLUSION: Prolonged outpatient RIST administration is feasible, and its role as multimodality consolidation warrants further prospective evaluation.